ADIL vs AMGN · $6.0M cap vs P/E 24, rev $10.05B
Adial Pharmaceuticals Inc (ADIL) versus Amgen Inc (AMGN) — a side-by-side from cached financials, not a winner call.
Adial Pharmaceuticals Inc (ADIL) is a biotechnology company listed on NASDAQ.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
ADIL does not have a complete income-statement cache yet.
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
ADIL currently screens at market cap $6.0M. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Not investment advice. Open the ADIL and AMGN stock pages for the full models.
Not investment advice.